الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 162 |  |  |
| | | from | 162 | | |
Abstract
The current treatment of HCV of peg IFN-a and ribavirin increase the SVR. Despite this, the morbidity and mortality rates associated with HCV are predicted to rise in the coming years, and more efficacious and tolerable therapies are urgently required. Understanding of the HCV life cycle has resulted in the development of several agents that target specific stages of the life cycle. The most common drugs are protease inhibitors such as telaprevir and boceprevir present in phase 3 clinical trial. polymerase inhibitors of the HCV RNA as HCV-796 present in phase 2. Host protein inhibitors as cyclophilin B inhibitor, α-glucosidase inhibitor and Nitazoxanide are safe and will tolerated with few side effects.